MedPath

KERYX BIOPHARMACEUTICALS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:0
Completed:10

Trial Phases

3 Phases

Phase 2:3
Phase 3:8
Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
8 (61.5%)
Phase 2
3 (23.1%)
Phase 4
2 (15.4%)

Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Phase 3
Not yet recruiting
Conditions
Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Interventions
Drug: standard of care
First Posted Date
2020-12-02
Last Posted Date
2023-10-23
Lead Sponsor
Keryx Biopharmaceuticals
Target Recruit Count
36
Registration Number
NCT04649411

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Phase 3
Recruiting
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
First Posted Date
2020-08-24
Last Posted Date
2025-04-16
Lead Sponsor
Keryx Biopharmaceuticals
Target Recruit Count
45
Registration Number
NCT04523727
Locations
🇺🇸

Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States

🇺🇸

University of Alabama at Birmingham (UAB) - Children's of Alabama, Birmingham, Alabama, United States

🇺🇸

Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 11 locations

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Phase 4
Completed
Conditions
Chronic Kidney Diseases
Iron Deficiency Anemia
Interventions
First Posted Date
2017-08-01
Last Posted Date
2021-03-12
Lead Sponsor
Keryx Biopharmaceuticals
Target Recruit Count
206
Registration Number
NCT03236246
Locations
🇺🇸

Arizona Kidney Disease and Hypertension center: AKDHC Medical Research Services, LLC, Phoenix, Arizona, United States

🇺🇸

California Institute of Renal Research, Poway, California, United States

🇺🇸

Denver Nephrologists, P.C., Denver, Colorado, United States

and more 21 locations

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Phase 3
Completed
Conditions
Anemia of Chronic Kidney Disease
Interventions
First Posted Date
2014-10-20
Last Posted Date
2018-03-22
Lead Sponsor
Keryx Biopharmaceuticals
Target Recruit Count
234
Registration Number
NCT02268994
Locations
🇺🇸

AKDHC Medical Research Services, LLC, Phoenix, Arizona, United States

🇺🇸

Southwest Kidney Institute, Tempe, Arizona, United States

🇺🇸

California Renal Research, Glendale, California, United States

and more 33 locations

A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia

Phase 2
Completed
Conditions
Anemia of Chronic Kidney Disease
Interventions
First Posted Date
2014-05-01
Last Posted Date
2018-08-24
Lead Sponsor
Keryx Biopharmaceuticals
Target Recruit Count
32
Registration Number
NCT02128074
Locations
🇮🇱

Barzilai Medical Center, Ashkelon, Israel

🇮🇱

Western Galilee Hospital, Nahariya, Israel

🇮🇱

Nazareth Hospital- EMMS, Nazareth, Israel

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath